PDCD1LG2 and neoplasm: Patients with low expression of tumor PD-L1 and PD-L2 had a higher risk for poor DFS: low tumor PD-L1 (HR=1.656, 95% CI=1.202-2.280, p=0.02) and low tumor PD-L2 (HR=1.296, 95% CI=0.955-1.759, p=0.096).